{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:50:49Z","timestamp":1782118249268,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Aspire Bariatrics"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.mcna.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T18:30:12Z","timestamp":1510943412000},"page":"135-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Obesity Pharmacotherapy"],"prefix":"10.1016","volume":"102","author":[{"given":"Katherine H.","family":"Saunders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devika","family":"Umashanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon I.","family":"Igel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha B.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J.","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25 Pt B","key":"10.1016\/j.mcna.2017.08.010_bib1","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.mcna.2017.08.010_bib2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2017.08.010_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ijo.2015.59","article-title":"Physiological adaptations to weight loss and factors favouring weight regain","volume":"39","author":"Greenway","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.mcna.2017.08.010_bib4","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/ijo.2010.184","article-title":"Adaptive thermogenesis in humans","volume":"34","author":"Rosenbaum","year":"2010","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"10.1016\/j.mcna.2017.08.010_bib5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/oby.21538","article-title":"Persistent metabolic adaptation 6 years after \u201cThe Biggest Loser\u201d competition","volume":"24","author":"Fothergill","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"10.1016\/j.mcna.2017.08.010_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2017.08.010_bib7","unstructured":"Adipex [package insert]. Tulsa, OK: Physicians Total Care, Inc; 2012."},{"key":"10.1016\/j.mcna.2017.08.010_bib8","unstructured":"Ionamin [package insert]. Rochester, NY: Celltech Pharmaceuticals, Inc; 2006."},{"key":"10.1016\/j.mcna.2017.08.010_bib9","unstructured":"Suprenza [package insert]. Cranford, NJ: Akrimax Pharmaceuticals, LLC; 2013."},{"key":"10.1016\/j.mcna.2017.08.010_bib10","unstructured":"Lomaira [package insert]. Newtown, PA: KVK-TECH, INC; 2016."},{"issue":"11","key":"10.1016\/j.mcna.2017.08.010_bib11","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"5588","key":"10.1016\/j.mcna.2017.08.010_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.mcna.2017.08.010_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/clpt.1994.104","article-title":"Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers","volume":"56","author":"Zhi","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.mcna.2017.08.010_bib14","unstructured":"Xenical [package insert]. South San Francisco, CA: Genentech USA, Inc; 2015."},{"key":"10.1016\/j.mcna.2017.08.010_bib15","unstructured":"Alli [package insert]. Moon Township, PA: GlaxoSmithKline Consumer Healthcare, LP; 2015."},{"issue":"1","key":"10.1016\/j.mcna.2017.08.010_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"7631","key":"10.1016\/j.mcna.2017.08.010_bib17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mcna.2017.08.010_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pcad.2013.09.005","article-title":"Weight loss strategies for treatment of obesity","volume":"56","author":"Kushner","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.mcna.2017.08.010_bib19","unstructured":"Qsymia [package insert]. Mountain View, CA: VIVUS, Inc; 2012."},{"key":"10.1016\/j.mcna.2017.08.010_bib20","unstructured":"Qsymia risk evaluation and mitigation strategy (REMS). VIVUS, Inc. Available at: http:\/\/www.qsymiarems.com\/. Accessed February 20, 2017."},{"issue":"2","key":"10.1016\/j.mcna.2017.08.010_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"10.1016\/j.mcna.2017.08.010_bib22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mcna.2017.08.010_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.mcna.2017.08.010_bib24","unstructured":"A study to evaluate the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors (CAMELLIATIMI). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02019264."},{"key":"10.1016\/j.mcna.2017.08.010_bib25","unstructured":"Belviq [package insert]. Zofingen, Switzerland: Arena Pharmaceuticals; 2012."},{"key":"10.1016\/j.mcna.2017.08.010_bib26","unstructured":"Belviq XR [package insert]. Zofingen, Switzerland: Arena Pharmaceuticals; 2016."},{"issue":"3","key":"10.1016\/j.mcna.2017.08.010_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2017.08.010_bib28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O\u2019Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"10.1016\/j.mcna.2017.08.010_bib29","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A\u00a0one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mcna.2017.08.010_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.mcna.2017.08.010_bib31","unstructured":"Contrave [package insert]. La Jolla, CA: Orexigen Therapeutics, Inc; 2016."},{"issue":"9741","key":"10.1016\/j.mcna.2017.08.010_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mcna.2017.08.010_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.mcna.2017.08.010_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.mcna.2017.08.010_bib35","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mcna.2017.08.010_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"Van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"10.1016\/j.mcna.2017.08.010_bib37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2017.08.010_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mcna.2017.08.010_bib39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"10.1016\/j.mcna.2017.08.010_bib40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/oby.21811","article-title":"Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study","volume":"25","author":"Smith","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.mcna.2017.08.010_bib41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc16-2427","article-title":"Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial","volume":"40","author":"Hollander","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.mcna.2017.08.010_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.soard.2016.10.018","article-title":"The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study","volume":"13","author":"Stanford","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.mcna.2017.08.010_bib43","unstructured":"Contrave [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2014."},{"key":"10.1016\/j.mcna.2017.08.010_bib44","unstructured":"Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk; 2014."}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712517301347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712517301347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T09:28:14Z","timestamp":1656062894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712517301347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0025712517301347"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2017.08.010","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity Pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}